Published on 2 Aug 2023 on Zacks via Yahoo Finance
Intercept Pharmaceuticals ICPT incurred a loss of 14 cents per share (from continuing operations) in second-quarter 2023, narrower than the Zacks Consensus Estimate of 56 cents. The company also reported a loss of 68 cents per share in the year-ago quarter.
Total revenues were $83.7 million, up 16.7% year over year. The top line beat the Zacks Consensus Estimate of $79 million.
Shares are up in pre-market trading.